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ABSTRACT 
Background: Patients with chronic hepatitis B virus (HBV) infection are at a high risk to 
develop hepatocellular carcinoma (HCC). Recently, metabolic syndrome has been found to 
carry a risk for HCC development. Considering the limitation of chemotherapeutic drugs for 
HCCs, the development of chemopreventive agents for high risk chronic HBV carriers is 
urgently demanded. In this study, we used combined silymarin and resveratrol extract which 
have been shown to exhibit biologic effects on activating peroxisome proliferator activated 
receptors (PPAR) and inhibiting mTOR signaling in a transgenic mice model harboring HBV 
viral oncoproteins.   
Methods: The transgenic mice model harboring HBx and pre-S2 mutant constructs which 
develop HCC was adopted. First, we in vitro tested the ideal combination dosages of the 
silymarin and resveratrol product, and then we fed the natural product to the transgenic mice. 
The chemopreventive effects on preventing the development of HCC were evaluated. 
Results: MTT assay showed an enhanced effect of the combined silymarin and resveratrol 
product on the reduction of cell proliferation in two hepatoma cell lines, Huh-7 and Hep G2. 
In vitro reporter assay and Western blot analyses revealed that the combined product could 
activate  PPAR/PGC-1  signaling  and  inhibit  mTOR  expression.  In  vivo,  the  combined 
products  could  significantly  ameliorate  fatty  liver  and  reduce  HCCs  in  transgenic  mice 
harboring HBV oncoproteins.   
Conclusions: The combined silymarin and resveratrol product exhibits a synergistic effect 
on  the  reduction  of  HCC  development  in  transgenic  mice  model  and  may  represent  a 
potential agent for the prevention of HCC in high risk chronic HBV carriers. Functional Foods in Health and Disease 2013; 3(9):341-352                                                  Page 342 of 352 
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INTRODUCTION:   
Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide and 
is the second most frequent cause of cancer death in men [1]. The major risk factors for HCC 
include chronic infection with  hepatitis  C virus (HCV) or hepatitis  B virus (HBV), and 
excessive  alcohol  consumption  [2].  Chronic  hepatitis  B  virus  (HBV)  infection  and 
HBV-related hepatocellular carcinoma (HCC) remain one of the major health problems in 
Taiwan, mainland China, and other parts of the world [3].
 Among the mechanisms of HBV 
hepatocarcinogenesis,  HBx  has  been  recognized  as  a  viral  oncoprotein  and  many 
HBV-related signal pathways have been reported to be potential oncopathways, including the 
recently reported mTOR (mamalian target of rapamycin) signaling [4-6]. Besides HBx, we 
proposed that the emergence of a second HBV oncoprotein, the pre-S2 deletion mutant in 
Type II ground glass hepatocytes (GGH) at the advanced stage of chronic HBV infection [7, 
8]. The pre-S2 deletion mutant can induce endoplasmic reticulum (ER) stress and initiate ER 
stress-dependent and -independent signals, leading to NF- -2 induction, 
oxidative DNA damage, and genomic instability [9-11]. The pre-S2 deletion mutants can 
also activate the VEGF-A and mTOR signal pathway [12, 13]. Therefore, GGHs are now 
recognized as a pre-neoplastic lesion of HCC and pre-S2 deletion mutant as a new viral 
oncoprotein. 
Although anti-viral drugs have been shown effective in controlling the HBV infection, 
the  progression  from  chronic  HBV  infection  to  HCC  still  remains  a  nightmare  for  the 
majority of chronic HBV carriers. Target drugs have been developed for therapeutic trial of 
HCC, but the efficacy is still limited. Furthermore, no chemopreventive agents or natural 
products have been tried to prevent or revert the disease progression from chronic HBV 
infection to HCC. The reasons for this difficulty to apply chemoprevention for HBV-related 
HCC is due to the lack of knowledge for the molecular mechanism of HBV tumorigenesis or 
the disease progression from their precursor lesions to HCC, and also the lack of suitable 
chemopreventive products. Recently, patients with metabolic syndrome have been found to 
carry a high risk to develop HCC [14, 15]. For chemoprevention of cancer development or 
recurrence, natural products with active ingredients and without side effects are most ideal 
considering the long-term usage.   
Besides HBV or HCV infection, nonalcoholic fatty liver disease, inflammation, and 
metabolic syndrome have been recognized to  be the risk factors for  HCC development. 
Furthermore,  small-sized  HCC,  either  HBV-  or  HCV-related,  frequently  showed  fatty 
change, suggesting that lipid metabolism is disturbed at the advanced stage of chronic liver 
disease and HCC [16, 17].
 Recently, mTOR signaling has been found to play a regulator role 
in  the  metabolic  syndrome  and  HBV  tumorigenesis  [18-20].  It  can  regulate  the  lipid 
biosythesis  through  the  SREBP-1  to  activate  peroxisome  proliferator  activated  receptors 
(PPAR)- and lipid-related genes which may contribute to tumorigenesis [18, 21, 22].   Functional Foods in Health and Disease 2013; 3(9):341-352                                                  Page 343 of 352 
Among  the  natural  products,  silymarin  is  the  ideal  candidate  product  for 
chemoprevention of HCCs because of their popular and long-term usage for chronic liver 
diseases  in  human  community  (23).  Silymarin,  a  compound  from  milk  thistle  (Silybum 
marianum), has been widely consumed as a dietary supplement and an empirical product 
widely used for liver diseases. The active component-silibinin has been evaluated clinically 
in  the  treatment  of  hepatitis  and  liver  damage  because  of  its  anti-inflammation  and 
anti-oxidant effects [23, 24]. Recent evidence also suggests that silymarin and silibinin may 
be useful in the chemoprevention of malignancies in a variety of sites including liver cancer 
[25, 26]. The other ideal candidate for HCC chemoprevention is the resveratrol from grape 
skin extract which has been verified to be effective to prevent cancer development at various 
stages of carcinogenesis including initiation, promotion, tumor invasion, and metastatsis [25, 
27-29]. Resveratrol is a strong anti-oxidant and anti- inflammatory agent [30, 31], and also a 
most promising product for metabolic syndrome and longevity through mTOR inhibition and 
upregulation of PPARs and PGC-1[31-33]. Therefore, the combination of silymarin and 
resveratrol will be a potential candidate for chemoprevention of HCCs in high risk chronic 
HBV carriers. 
In this study, the in vitro and in vivo effects of silymarin and resveratrol, either alone or 
in combination, were evaluated in inhibiting the proliferation of HCC cell lines by MTT 
assay. Their activities in regulating PPARs, PGC-1 and mTOR activities were tested by the 
reporter assay or Western blot analyses. The ideal combination of these two products were 
then fed to the transgenic mice harboring the double HBV oncoproteins (HBX and pre-S2 
mutants) for chemoprevention of HCC development.   
 
METHODS: 
Cell proliferation assay 
A total 5×10
3 cells/well was seeded in the 96 well plate. After treatment of silymarin (Sigma, 
St. Louis, MO), resveratrol (Calbiochem, Darmstadt, Germany), or both for 24 hour and 48 
hour, Cell Counting Kit-8 solution (Sigma, St. Louis, MO)) was added to each well and then 
incubated the plate for three hours at 37℃ . Then the plate was measured the absorbance at 
450 nm. 
Luciferase reporter assay 
PPAR--LBD  and  pRL-TK  plasmids  were  used  in  PPAR-  activity  analysis.  After 
transfection with lipofectamine 2000 (Invitrogen, Carlsbad, CA92008), luciferase-expressed 
cells were assayed by the Dual-Luciferase Reporter Assay System (Promega, Madison, Wl, 
USA),  according  to  the  manufacturer’s  instructions.  Renilla  luciferase  activities  were 
measured for normalization.     
Western blot analyses 
Cells were harvested after treated with silymarin, resveratrol, or both for 48 hours and then 
lysed in RIPA buffer (Upstate Biotechnology, NY) containing proteinase inhibitor cocktail 
and phosphatase inhibitor (Roche Applied Science, Indianapolis, IN). Total protein lysate 
was then harvested via centrifugation at 13,000 rpm for 20 minutes, resolved on SDS-PAGE 
and transferred to PVDF membranes. After incubated with primary antibodies and following Functional Foods in Health and Disease 2013; 3(9):341-352                                                  Page 344 of 352 
secondary antibodies, the membranes were visualized by ECL (PerkinElmer Life Science, 
Boston,  MA).  Antibodies  used  in  this  study  were  anti-PPAR-  (Abcam,  MA,  USA), 
anti- -SIRT1  (Abcam,  Cambridge,  UK), 
anti-p-mTOR (Abcam, Cambridge, UK) and anti--actin (Chemicon, Temecula, CA). 
Transgenic animal model harboring double HBx and pre-S2 mutant constructs 
Transgenic mice harboring HBx and pre-S2 mutant were established using the liver-specific 
transgenic vector pAlb-In-pA-HS4 as described previously [26]. The albumin-HBx or pre-S2 
mutant (nt 4-57 deletion) [9] transgenic mice were generated by pronucleus microinjection 
of C57BL/6 fertilized eggs. The transgenic mice harboring both HBx and pre-S2 mutants 
were obtained by hybridizing the HBx-transgenic mice and pre-S2 mutant-transgenic mice. 
The  HBx  and  pre-S2  mutant  transgenic  mice  are  bred  and  screened  for  the  HCC 
chemoprevention study. All of the mice used in this study were male and housed in a specific 
pathogen free facility. All the animal experiments have been performed under the approval 
of  the  Institutional  Animal  Care  and  Use  Committees  of  the  National  Cheng  Kung 
University Medical School and National Health Research Institutes. 
Preparation of natural products for chemoprevention         
The  natural  product-silymarin  was  purchased  from  Indena  (Indena,  Milan,  Italy).  This 
product is an extract from Milk Thistle and contained 35% silybin in a phytosome complex 
as assayed by HPLC. The natural product-Vineatrol
® 20-6 was purchased from Breko (Breko 
GmbH,  Bremen,  German).  This  product  is  an  extract  from  grape  vine  and  contained 
resveratrol of 20% as revealed by HPLC assay. Silymarin (0.875 mg Silymarin/g chow), 
resveratrol (0.875 mg Vineatrol
®/g chow), or both were added and mixed with normal chow 
diet. 
Animal study for HCC chemoprevention 
Four groups of transgenic mice were fed with normal chow diets or chow diets containing 
silymarin, resveratrol or both at the age of 8 months for six months (at the age of 14 months) 
and  then  sacrificed  for  evaluation.  The  residual  chow  diets  were  weighed  weekly  for 
controlling amount of mice uptake. These mice were weighed each week and measured ALT 
monthly. The tumor development (including tumor size and tumor number) in each group 
was evaluated and analyzed by biostatistics.   
Histopathology 
Mice were sacrificed after being fed natural products for 6 months. Liver tissues were then 
collected,  fixed  with  10%  neutral  formalin,  and  embedded  in  paraffin.  These 
paraffin-embedded liver tissues were sectioned at 4 m thickness and further subjected to 
hematoxylin-eosin  (H&E)  staining  for  conventional  histopathological  observation.  Fat 
accumulation in liver was examined by Oil-Red O staining of cryostat frozen sections as 
described previously [34].   
Statistical analysis 
Statistical  analyses  were  carried  out  using  GraphPad  Prism  4.  Data  was  analyzed  by Functional Foods in Health and Disease 2013; 3(9):341-352                                                  Page 345 of 352 
Kruskal-Wallis test and Dunn’s post test. P value <0.05 was considered significant. 
 
RESULTS and DISCUSSIONS: 
In Vitro Study: enhanced activity of combined silymarin and resveratrol product on the 
inhibition of tumor cell proliferation 
We first tested the effect of silymarin and resveratrol on two hepatoma cell lines, Huh-7 and 
Hep-G2. Different doses of silymarin (0, 25, 50, 100 and 200 g/ml) and resveratrol (0, 10, 
20, and 40 g/ml) were studied by MTT assay on both cell lines. The results showed a 
reduction of cell proliferation on both Huh 7 and Hep G2 cell lines. The best combination 
dosage for the anti-proliferation effect on both cell lines were determined at around the ratio 
of 1:2.5-1:5 for resveratrol and silymarin, respectively in combination (Figure 1). 
 
 
Figure 1. Anti-proliferation effect of resveratrol combined with silymarin on Huh-7 hepatoma 
cell line 
 
We then determined the effects of the combined product on the regulation of PPAR, 
PGC-1andp-mTOR. Resveratrol has been reported that can activate PGC-1 which acts 
as a co-activator of PPAR-. We chose 100 g/ml silymarin combined with 40 or 80 M 
resveratrol based on the above-described MTT results to test their effects on the regulation of 
PPAR-PGC-1and p-mTOR. The PPAR- activities were determined by the luciferase 
reporter assay, while Western blot analyses were used to evaluate the expression of PGC-1 
and p-mTOR. Our results showed that resveratrol combined with silymarin had synergistic 
effects on increasing the PPAR-activities in both Huh-7 and Hep-G2 cell lines (Figure 2A). Functional Foods in Health and Disease 2013; 3(9):341-352                                                  Page 346 of 352 
Western blot analyses showed that the combined silymarin (100 g/ml) and resveratrol (80 
M)  exhibited  the  significant  enhanced  activities  to  inhibit  mTOR  and  increased 
PGC-1Figure   
 
Figure  2.  Synergistic  effect  of  resveratrol  combined  with  silymarin  on  PPAR-  activity, 
p-mTOR inhibition, and enhanced PGC-1 
 
Considering the absorbability and catabolism in vivo, we then performed a pilot in vivo 
study for testing the effects of the different dosages of the combined product on mice. 
 
In Vivo dosage test 
In this study, we used 4-week-old of HBx transgenic male mice (C57BL/6 background) for 
testing the effect of combined product on the early stage of liver pathogenesis. The HBx 
transgenic  male  mice  and  their  wild  type  male  littermates  were  randomly  assigned  into 
different groups. Resveratrol (20 mg/kg) combined with various doses of silymarin (15, 30, 
and 60 mg/kg) were fed to mice daily through p.o administration using feeding needles for 
two weeks (14 days) and then mice were sacrificed for analysis. From H&E and oil-red 
staining, the liver of HBx-transgenic mice without any treatment showed minor fatty change 
at the age of 6 weeks, but it improved after treatment of resveratrol (20 mg/kg) combined 
with Silymarin (15 mg/kg, 30 mg/kg and 60 mg/kg). The HBx transgenic livers recovered to 
almost normal morphology in the group of 20 mg/kg resveratrol combined either 30 mg/kg 
silymarin or 60 mg/kg silymarin group. In the group of 20 kg/ml resveratrol combined with 
silymarin 30 mg/kg, it showed significant improvement of fatty change as compared to the 
group of either resveratrol or silymarin alone (Figure 3A and 3B).   Functional Foods in Health and Disease 2013; 3(9):341-352                                                  Page 347 of 352 
 
 
Figure 3. Beneficial effects of resveratrol combined with silymarin on liver damage and 
fatty changes. 
 
Toxicity studies 
Serum ALT observed in both wild-type and HBx transgenic mice are in a normal range 
(20-50 U/L) at the age of 4-6 weeks. No obvious difference in the serum ALT was detected 
among  control  and  treatment  groups.  Taken  together  the  liver  pathology  and  serum 
biochemistry, the findings indicate that resveratrol (20 mg/kg), silymarin (15, 30 and 60 
mg/kg)  or  the  combined  product  showed  no  toxic  effect  on  liver  at  this  age  of  mice. 
Therefore, the combination of these two natural products (20 kg/ml resveratrol and 30 kg/ml 
silymarin) will be a safe agent for chemopreventon on HBV-related HCC animal model. 
Chemoprevention design based on the molecular mechanism of HBV tumorigenesis by 
using  the  combined  products  on  transgenic  mice  harboring  both  HBx  and  pre-S2 
mutant     
Recently, we demonstrated that GGHs co-expressing both HBx and pre-S2 mutant exhibited 
an enhanced tumorigenesis pertinent to human HBV/HCC development. A transgenic animal 
model  harboring  the  double-construct  HBx  and  pre-S2  mutant  has  been  successfully 
established in our laboratory and was adopted in this study for chemoprevention study. The 
study design is based on the molecular mechanism of HBV tumorgenesis we previously 
proposed [34] (Figure 4). 
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Figure  4.  Design  of  chemoprevention  based  on  the  molecular  mechanism  of  HBV 
tumorigenesis. 
 
Tumor development was reduced in transgenic mice harboring double HBx plus pre-S2 
mutants fed with combined silymarin and resveratrol product 
The natural product for chemoprevention is prepared by combining extracts of silymarin and 
resveratrol,  based on the concentration and dosages  used in  in  vitro and  in  vivo dosage 
studies. The component of the extract for resveratrol is 20% purity, while that of silymarin is 
35%  purity  based  on  the  HPLC  profile  analyses  provided  by  the  manufacturers.  These 
products were prepared as chow diets to feed the transgenic mice (4 g chow/mouse/day), 
including  control  group  (normal  chow  diets),  silymarin  group,  resveratrol  group  and 
combined silymarin plus resveratrol group. In the transgenic mice harboring double HBx and 
pre-S2 constructs, the results showed that tumor development was significantly reduced in 
the group fed with resveratrol or silymarin alone, or in the combined product group (Figure 
5). However, the combined product showed remarkable for the tumors lager than 5 mm 
diameter,  from  50%  in  the  control  group  to  12.5%  in  the  combined  product  group,  as 
compared to that in the group of resveratrol (45 %) or silymarin (47%) alone. The data 
indicate that the combined resveratrol and silymarin product exhibited a synergistic effect on 
reducing  HCC  development  in  this  transgenic  mice  model  which  is  pertinent  to  human 
HBV-related HCC. In this study, to ensure whether other ingredients in these extracts have 
additional effects, these chow diets (containing silymarin, resveratrol or both) were also fed 
to  wild-type  mice  (for  control  and  toxicity  observation).  Both  ALT  in  serum  and  liver 
pathology showed no abnormal change after feeding these diets.   
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Figure 5. Tumor development in transgenic mice was significantly reduced in the group of 
feeding combined silymarin and resveratrol product. 
 
CONCLUSION: 
In this study, our in vitro studies revealed that resveratrol could activate the PGC-1 and 
PPAR signaling and reduce cell proliferation in the two hepatoma cell lines by MTT assay. 
We also verified that the combined product can exhibit inhibition on mTOR signaling which 
represents an important  mechanism in HBV tumorigenesis. Our results in the transgenic 
mice  harboring  double  HBx  and  pre-S2  mutant  construct  showed  that  the  combined 
silymarin  and  resveratrol  product  at  a  defined  ratio  of  dosages  may  represent  an  ideal 
candidate agent for chemoprevention of HCCs because of their popular and long-term usage 
in human community. Silymarin and resveratrol have been reported to be effective at various 
stages  of  carcinogenesis  including  initiation,  promotion,  tumor  invasion,  and  metastatsis 
[25-27, 29].
   Clinical trial will be designed along this line to conduct on high risk chronic 
hepatitis B patients to prevent HCC development or to prevent the recurrence of their HCC 
after surgery. 
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